Medicenna Therapeutics Corp
Open
$0.59
Prev. Close
$0.59
High
$0.59
Low
$0.59
Market Snapshot
$81.34M
-0.16
18
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 16 full-time employees. The company went IPO on 2015-07-13. The firm's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program Targeted Metalloprotease Activated SuperKine (T-MASK) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.
emptyResult
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 16 full-time employees. The company went IPO on 2015-07-13. The firm's principal business activity is the development and commercialization of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program Targeted Metalloprotease Activated SuperKine (T-MASK) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.
Recently from Cashu
Medicenna Therapeutics Corp. Achieves Significant Financial Improvement for FY 2025
Medicenna Therapeutics Corp. Reports Improved Financial Performance for Fiscal Year 2025 Medicenna Therapeutics Corp. announces its financial results for the fiscal year ending March 31, 2025, showcas…
Medicenna Therapeutics Corp. Outlines Strategic Focus Amid Financial and Development Challenges
Medicenna Therapeutics Highlights Strategic Focus Amid Financial Landscape Medicenna Therapeutics Corp. releases its Management's Discussion and Analysis (MD&A) for the fiscal year ending March 31, 20…
Medicenna Therapeutics Corp. Reports Financial Gains and Advances in Therapeutic Platforms
Medicenna Therapeutics Corp. Advances Therapeutic Platforms Amid Financial Improvement Medicenna Therapeutics Corp. showcases a pivotal moment in its evolution with the release of its Management's Dis…